碱性成纤维细胞生长因子对大鼠肾小球系膜细胞原癌基因c-fos和c-myc表达的影响

在建立大鼠肾小球系膜细胞（ＭＣ）体外培养方法的基础上,通过３Ｈ－ＴｄＲ参入实验,ＲＮＡ印迹分析和斑点杂交观察ｂＦＧＦ对ＭＣＤＮＡ合成及原癌基因ｃ－ｆｏｓ和ｃ－ｍｙｃ表达的影响．结果表明,ｂＦＧＦ作用于ＭＣ１８ｈ,ＭＣ的３Ｈ－ＴｄＲ参入率明显增加（Ｐ＜０．０５）,２４ｈ达到高峰（Ｐ＜０．０１）;ｂＦＧＦ显著诱导原癌基因ｃ－ｆｏｓ和ｃ－ｍｙｃ表达,其表达活性分别于３０ｍｉｎ和１ｈ达到高峰．提示ｂＦＧＦ是ＭＣ的强效丝裂原,其对ＭＣＤＮＡ合成的促进作用与诱导原癌基因ｃ－ｆｏｓ和ｃ－ｍｙｃ表达有关．     

核酶对bcl－2mRNA的体外切割

通过微机对ｂｃｌ－２ＲＮＡ二级结构的分析,设计针对ｂｃｌ－２片段５＇ＣＧＣＧＡＣＣＣＧＧＵＣＧＣＣＡＧＧＡＣＣＵＣＧ３＇的“锤头状”（Ｈａｍｍｅｒｈｅａｄ）核酶（Ｒｉｂｏｚｙｍｅ,ＲＤ）基因,平端连接于ｐＧＥＭ－３Ｚｆ（－）ＨｉｎｃⅡ位点,克隆后经测序表明序列正确,ｂｃｌ－２和Ｒｉｂｏｚｙｍｅ基因经体外转录,５０℃作用２ｈ,从１６５６－１６５７（Ｃ－Ｇ）位之间切断ｂｃｌ－２ＲＮＡ片段．     

人主动脉硫酸乙酰肝素蛋白聚糖对培养的人血管壁细胞生长的作用

通过培养的人主动脉平滑肌细胞（ｈＡＳＭＣ）及脐静脉内皮细胞（ｈＵＶＥＣ）,应用３Ｈ－ＴｄＲ参入、Ｎｏｒｔｈｅｒｎｂｌｏｔ分析、逆转录多聚酶链反应（ＲＴ－ＰＣＲ）、放射免疫分析（ＲＩＡ）、和紫外比色法等技术观察了人主动脉中硫酸乙酰肝素蛋白聚糖（ＨＳＰＧ）对ｈＡＳＭＣ和ｈＵＶＥＣＤＮＡ合成的作用及对血小板源生长因子（ＰＤＧＦ）、ＰＤＧＦ受体、转化生长因子β（ＴＧＦ－β）、内皮素－１（ＥＴ－１）或碱性成纤维细胞生长因子（ｂＦＧＦ）基因表达和肾素－血管紧张系统（ＲＡＳ）的影响,结果显示,ＨＳＰＧ明显抑制培养的ｈＡＳＭＣ基础的ＤＮＡ合成（ｃｐｍ值为：１０３８５±３２６３ｖｓ,２５５４１±６４２１,Ｐ＜０．０１）及外源性ＰＤＧＦ诱导的ＤＮＡ合成（ｃｐｍ值为：９８７８±１９４７ｖｓ．１３４８１±４４ｌ０,Ｐ＜０．０５）;抑制ＰＤＧＦＡ链、ＴＧＦ－Ｂｐ和ＥＴ－１ｍＲＮＡ表达,提高ＰＤＧＦａ和β受体ｍＲＮＡ的表达;显著降低ｈＡＳＭＣ培养液中血管紧张素Ⅱ（ＡｎｇⅡ）的浓度和血管紧张素转换酶（ＡＣＥ）的活性,推测ＨＳＰＧ抑制ＰＤＧＦＡ链、ＴＧＦ－β及ＥＴ－１ｍＲＮＡ表达,降低ＡＣＥ活性及ＡｎｇⅡ浓度是其抑制ｈＡＳＭＣ增殖的重要机     

用pKKH质粒在大肠杆菌中表达HuIFN－β

应用ＤＮＡ重组技术,将ＨｕＩＦＮ－β基因插入到质粒ｐＫＫＨ的ｔａｃ启动子下游,转化大肠杆菌ＪＭ１０１和ＪＭ１０３,经ＩＰＴＧ诱导,表达ＨｕＩＦＮ－β,收集并裂解细菌,用Ｗｉｓｈ－ＶＳＶ系统细胞病变抑制法检测生物学活性为２．１８×１０８－８．７×１０８ＩＵ／Ｌ菌液。经初步纯化ＳＤＳ－ＰＡＧＥ电泳可见分子量为２０ＫＤ较纯的表达带。     

大鼠卵巢绒毛膜促性腺激素受体在CHO中的表达和扩增

本文报道了利用二氢叶酸还原酶放大系统将大鼠ＬＨ／ｈＣＧ受体（记为Ｆ－ｈＣＧＲ）及其胞外肽段（记为Ｔ－ｈＣＧＲ）在中国苍鼠卵巢细胞（ＣＨＯ）中的表达。ＳＤＳ－ＰＡＧＥ分析表明,Ｆ－ｈＣＧＲ为一条蛋白质带,其表观分子量为９２ｋｄ,而Ｔ－ｈＣＧＲ为３５ｋｄ和３７ｋｄ两条带。表达受体对其配基ｈＣＧ表现出高的亲合力,Ｆ－ｈＣＧＲ的解离常数为７×１０－９ｍｏｌ／Ｌ,Ｔ－ｈＣＧＲ为６．４×１０－９ｍｏｌ／Ｌ。表达Ｆ－ｈＣＧＲ的转染ＣＨＯ细胞可结合１２５Ｉ－ｈＣＧ,而表达Ｔ－ｈＣＧＢ者不结合１２５Ｉ－ｈＣＧ。这提示Ｆ－ｈＣＧＲ主要存在于细胞质膜表面上。表达Ｆ－ｈＣＧＲ的转染ＣＨＯ细胞能刺激。ｃＡＭＰ的形成,而表达Ｔ－ｈＣＧＲ者不能刺激ｃＡＭＰ形成。免疫荧光定位结果表明,Ｔ－ｈＣＧＲ主要分布于质膜的细胞质侧以及胞内其他一些细胞器膜上。用免疫亲和层析可以得到纯化的Ｔ－ｈＣＧＲ。     

L－异亮氨酸产生菌选育的研究

以黄色短杆菌（Ｂｒｅｖｉｂａｃｔｅｒｉｕｍｆｌａｖｕｍ）ＡＴＣＣ１４０６７为出发菌株,经硫酸二乙酯（ＤＥＳ）、紫外线（ＵＶ）和亚硝基胍（ＮＴＧ）逐级诱变处理,α－氨基－β－羟基戊酸（ＡＨＶ）、Ｓ－２－氨基乙基－Ｌ－半胱氨酸（ＡＥＣ）、磺胺胍（ＳＧ）、乙硫氨酸（Ｅｔｈ）、α－氨基丁酸（α－ＡＢ）、异亮氨酸氧肟酸（ＩｌｅＨｘ）等氨基酸结构类似物及琥珀酸为碳源平板定向筛选,获得一株Ｌ－异亮氨酸高产菌ＺＱ－４（ＡＨＶ~γ、ＡＥＣ~γ、ＳＡＭ~γ、ＳＧ~γ、Ｅｔｈ~γ、α－ＡＢ~γ、ＩｌｅＨｘ~γ）在含１３．５％葡萄糖培养基中,摇瓶发酵７２ｈ、Ｌ－异亮氨酸积累可达２．８－３．０％。     

TGF－β家族及其受体组成

ＴＧＦ－β家族及其受体组成ＴｈｅＴＧＦ－βｆａｍｉｌｙａｎｄｉｔｓｃｏｍｐｏｓｉｔｅｒｅｃｅｐｔｏｒｓＪｏａｎ　Ｍａｓｓａｇｕｅ,ＬｉｌｉａｎａＡｔｔｉｓａｎｏａｎｄＪｅｆｆｒｅｙＬＷｒａｎａ￥／／张德胜译,曹惠婷校阅（中国科学院上海生物化学研究所２...     

L－异亮氨酸产生菌选育的研究

以黄色短杆菌（Ｂｒｅｖｉｂａｃｔｅｒｉｕｍｆｌａｖｕｍ）ＡＴＣＣ１４０６７为出发菌株,经硫酸二乙酯（ＤＥＳ）、紫外线（ＵＶ）和亚硝基胍（ＮＴＧ）逐级诱变处理,α－氨基－β－羟基戊酸（ＡＨＶ）、Ｓ－２－氨基乙基－Ｌ－半胱氨酸（ＡＥＣ）、磺胺胍（ＳＧ）、乙硫氨酸（Ｅｔｈ）、α－氨基丁酸（α－ＡＢ）、异亮氨酸氧肟酸（ＩｌｅＨｘ）等氨基酸结构类似物及琥珀酸为碳源平板定向筛选,获得一株Ｌ－异亮氨酸高产菌ＺＱ－４（ＡＨＶ~γ、ＡＥＣ~γ、ＳＡＭ~γ、ＳＧ~γ、Ｅｔｈ~γ、α－ＡＢ~γ、ＩｌｅＨｘ~γ）在含１３．５％葡萄糖培养基中,摇瓶发酵７２ｈ、Ｌ－异亮氨酸积累可达２．８－３．０％。     

环腺苷一磷酸对人Ⅰ型17β羟类固醇脱氢酶在绒癌细胞系中表达的调节作用

由Ｈ ＳＤ１７Ｂ１基因编码的人Ⅰ型１７β－羟类固醇脱氢酶（１７β－ｈｙｄｒｏｘｙｓｔｅｒｏｉｄｄｅｈｙｄｒｏｇｅｎａｓｅｔｙｐｅ１简称Ⅰ型１７ＨＳＤ）催化雌酮与雌二醇之间的转化。本文研究环腺苷一磷酸简化（ｃＡＭＰ）对该酶在培养的绒癌胞系（ＪＡＲ和ＪＥＧ－３）中表达的调节作用。用８－ｂｒｏｍｏ－ｃＡＭＰ处理两种绒癌细胞后,观察到在伴随１．３ｋｂⅠ型１７ＨＳＤｍＲＮＡ表达的同时,Ｉ型１７ＨＳＤ蛋白浓度     

铕螯合剂DTTAEuNa标记流行性出血热单克隆抗体的实验研究

用Ｎ′（对异硫氰基苄基）二乙三胺Ｎ１,Ｎ２,Ｎ３四乙酸铕钠（ＤＴＴＡＥｕＮａ）作为螯合剂,标记不同蛋白浓度的流行性出血热单克隆抗体（ＥＨＦＭｃＡｂ）,经ＳｅｐｈａｋｅｘＧ５０凝胶柱分离标记的单抗分子,通过对层析液的紫外吸收峰处的蛋白光密度,时间分辨荧光强度以及免疫活性测定表明：二批Ｅｕ标记单抗的比活性分别为７８和１４７个Ｅｕ３＋／ＥＨＦＭｃＡｂ,标记回收率分别为４１％和４２％,标记物的免疫活性良好,可用于流行性出血热的抗原及抗体检测     

^131I标记Tyr-GX1在荷瘤裸鼠体内分布和显像研究

目的：设计、合成酪氨酸（Tyr）修饰的肿瘤血管靶向肽GX1,研究^131I标记短肽Tyr-GX1在荷人胃癌裸鼠体内的生物学分布与显像,探讨^131I-Tyr-GX1短肽作为肿瘤血管靶向诊治药物的可能性。方法：利用Iodogen碘标法对Tyr-GX1进行131I标记,检测其标记率和体内外稳定性;建立荷人胃癌裸鼠动物模型,尾静脉注射标记肽,分别进行体内生物学分布实验和肿瘤显像实验,结果用PASW Statistics18.0统计软件进行分析。结果：1）.纸层析法结果计算表明,^131I-Tyr-GX1肽的标记率和放化纯均达90%以上;24 h稳定性测试表明,^131I-Tyr-GX1在室温下存放以及与人血清、鼠血清、PBS等溶液混合,其标记率仍然都维持在90%左右,说明其具有良好的体内外稳定性;2）.荷瘤裸鼠体内生物学分布研究显示：标记肽在荷瘤裸鼠双肾放射性计数测量最高;其次是肝脏、肿瘤等组织;脑、骨、肌肉组织放射性计数含量较低,给药24 h时,肿瘤/肌肉（T/M）、肿瘤/血液（T/Bl）、肿瘤/脑组织（T/Br）的放射性比值分别是5.78、4.06和23.01;3）.体内SPECT显像结果显示：尾静脉注射^131I-Tyr-GX1肽后4 h肿瘤部位已开始显影,并随时间的延长,显像逐渐清楚,至18 h时,肿瘤显像最清晰。结论：应用Iodogen碘标法成功标记Tyr-GX1短肽;尾静脉注射^131I-Tyr-GX1后,肿瘤部位可以出现放射性浓聚,表明^131I-Tyr-GX1短肽可以靶向结合于肿瘤部位,有望成为新一种胃肠道肿瘤诊断与治疗的药物。     

IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression

Proinflammatory cytokine TNFα plays critical roles in promoting malignant cell proliferation, angiogenesis, and tumor metastasis in many cancers. However, the mechanism of TNFα-mediated tumor development remains unclear. Here, we show that IKKα, an important downstream kinase of TNFα, interacts with and phosphorylates FOXA2 at S107/S111, thereby suppressing FOXA2 transactivation activity and leading to decreased NUMB expression, and further activates the downstream NOTCH pathway and promotes cell proliferation and tumorigenesis. Moreover, we found that levels of IKKα, pFOXA2 (S107/111), and activated NOTCH1 were significantly higher in hepatocellular carcinoma tumors than in normal liver tissues and that pFOXA2 (S107/111) expression was positively correlated with IKKα and activated NOTCH1 expression in tumor tissues. Therefore, dysregulation of NUMB-mediated suppression of NOTCH1 by TNFα/IKKα-associated FOXA2 inhibition likely contributes to inflammation-mediated cancer pathogenesis. Here, we report a TNFα/IKKα/FOXA2/NUMB/NOTCH1 pathway that is critical for inflammation-mediated tumorigenesis and may provide a target for clinical intervention in human cancer.     

131I]metaiodobenzylguanidine treatment of a malignant paraganglioma.

The bone metastases of a malignant, non-secreting paraganglioma were treated with [131I]metaiodobenzylguanidine (131I-MIBG) over a 10-year period. Initial treatment (131I-MIBG: 9.6 GBq) resulted in a decrease in the number of bone metastases from 16 to 2. At three years, a relapse with primary tumor regrowth and liver metastasis was again treated with 131I-MIBG (22.2 GBq). A decrease in the number of bone metastases and MIBG uptake was again observed.     

Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers

Derivatives of the somatostatin analogues octreotide and octreotate labeled with radioiosotopes are used in the diagnosis and therapy of somatostatin receptor (SSTR)-positive tumors. A method has been devised to synthesize {N-(4-guanidinomethyl-3-iodobenzoyl)-Phe1-octreotate (GMIBO). Receptor binding assay and scatchard analysis yielded a Kd of 4.83 +/- 0.19 nM for this peptide. Derivatives of this peptide labeled with radioiodine ([*I]GMIBO) and the alpha-particle-emitting radiohalogen 211At N-(3-[211At]astato-4-guanidinomethylbenzoyl)-Phe1-octreotate; [211At]AGMBO} were prepared in a single step from a tin precursor in radiochemical yields of 30-35% and 15-20%, respectively. Paired-label internalization assays performed with the SSTR-positive D341 Med human medulloblastoma cell line demonstrated that [125I]GMIBO and [211At]AGMBO were specifically internalized 20-40% more than Nalpha-(1-deoxy-D-fructosyl)-[131I]I-Tyr3-octreotate ([131I]I-Glu-TOCA), the radioiodinated octreotide derivative previously shown to exhibit maximum internalization in this cell line. Uptake of [131I]GMIBO in D341 Med subcutaneous xenografts in a murine model (8.34 +/- 1.82 versus 8.10 +/- 2.23% ID/g at 1h) and SSTR-expressing normal tissues was comparable to that of [125I]I-Glu-TOCA and was shown to be specific. However, the uptake of [131I]GMIBO also was substantially higher in liver (16.9 +/- 3.15 versus 1.39 +/- 0.45% ID/g at 1 h) and in kidneys (44.33 +/- 6.47 versus 3.44 +/- 0.68% ID/g at 1h) compared to that of [125I]I-Glu-TOCA. These data suggest that these novel peptide conjugates retain their specificity for SSTR both in vitro and in vivo; however, because of their higher accumulation in normal tissues they would be best applied in settings amenable to loco-regional administration such as medulloblastoma neoplastic meningitis.     

FAM96A和FAM96B结构与功能的研究进展

96序列相似的家庭成员A和B（family with sequence similarity 96 member A and B,FAM96A和FAM96B）是属于MIP18（MMS19-interacting protein of 18 kD）家族的2个高度保守的同源蛋白,MIP18是与有丝分裂纺锤体相关的MMDX（MMS19-MIP18-XPD）复合体的亚基。研究表明,FAM96A和FAM96B在人胃肠道间质瘤、结肠癌、肝癌、胃癌和乳腺癌等多种肿瘤组织中的表达显著降低,提示其可能是作为潜在的抑癌基因参与肿瘤的发生发展,但目前关于FAM96A和FAM96B在肿瘤发生发展过程中的作用机理并不十分清楚。此外,研究发现FAM96A和FAM96B可通过与其他不同的蛋白质相互作用在体内发挥多种不同的功能。因此,就目前对于FAM96A和FAM96B结构和功能的研究所取得的进展进行了回顾与总结,并对其在肿瘤发生发展中的分子机制和相互作用蛋白鉴定的研究前景进行了展望,以期为临床上将FAM96A和FAM96B作为新的肿瘤诊断标志物和治疗靶点奠定基础,并为揭示二者在体内更多的新功能提供依据。     

Deregulation of alternative splicing of fibronectin pre-mRNA in malignant human liver tumors

Alternative splicing of fibronectin pre-mRNA at the ED-A region has been shown to be regulated in a tissue- and developmental stage-specific manner. We investigated the splicing pattern at this region in malignant and nonmalignant human liver tissues and found that the relative population of the fibronectin mRNA containing the ED-A sequence is markedly increased in malignant liver tumors. Nontumorous liver tissues including those with chronic hepatitis and cirrhosis did not show any significant change in the alternative splicing at the ED-A region. It was also found that the increased expression of the ED-A-containing fibronectin mRNA closely correlates with the occurrence of portal vein tumor thrombus and intrahepatic metastasis, which are two characteristic features of invasive liver tumors. These results indicate that tissue-specific alternative splicing of fibronectin mRNA is modified in human liver cancer and raise a possibility that the putative molecular machinery governing alternative RNA splicing of not only fibronectin but also other cellular proteins is deregulated in malignant human tumors.     

Increases in mRNA levels of glucose transporters types 1 and 3 in Ehrlich ascites tumor cells during tumor development

A common feature of many tumors is an increase in glucose catabolism during tumor growth. We studied the mechanism of this phenomenon by using Ehrlich ascites tumor bearing mice as the animal model. We found that Ehrlich ascites tumor cells possess only glucose transporter 1 (GLUT1) and GLUT3 but no GLUT2, GLUT4, or GLUT5. The mRNA levels of GLUT1 and GLUT3 increased progressively in the tumour during development; however, there were no changes observable in mRNA levels of glucose transporters of all types in brain, liver, and heart of the host mice. These findings suggest that Ehrlich ascites tumor augments its glucose transport mechanism relative to other tissues in response to its unique growth needs. J. Cell. Biochem. 67:131–135, 1997. © 1997 Wiley-Liss, Inc.     

Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma

Enzyme activity, protein contents, and mRNA contents of group II phospholipase A₂ (PLA₂) in hepatocellular carcinoma (HCC) surgically obtained from 8 patients were compared with those in either its neighboring liver tissues or control liver tissues. The PLA₂ specific activity towards the mixed micelles of 1-palmitoyl-2-oleoyl-phosphatidylglycerol and cholate was significantly greater in the tumor tissues (6.62 ± 1.46 nmol/min/mg) than those in the surrounding liver tissues (1.33 ± 0.22 nmol/min/mg) and controls (0.43 ± 0.04 nmol/min/mg). The results of immunoblot analysis using a specific anti-human group II PLA₂ antibody and of Northern blot analysis using a human group II PLA₂ cDNA as a probe demonstrated that group II PLA₂ was responsible for the increased enzyme activity. The contents of immunoreactive group II PLA₂ in the tumor tissues (8.81 ± 1.24 ng/mg) were significantly higher than those in the surrounding liver tissues (1.77 ± 0.27 ng/mg); those in the control tissues were below the analytical range of the method used. The group II PLA₂ mRNA was also significantly increased in the tumor tissues, compared with that in the surrounding liver tissues, whereas it was not detectable in th controls. This indicates that group II PLA₂ in HCC is induced at the pretranslational level.     

Tissue and species distribution of liver type and tumor type nuclear poly(A) polymerases

Previous studies in this laboratory have identified two distinct nuclear poly(A) polymerases, a 48 kDA tumor type enzyme and a 36-38 kDA liver type enzyme. To investigate the tissue and species specificity of these enzymes, nuclear extracts were prepared from various rat tissues, pig brain and two human cell lines. These as well as whole cell extract from yeast were probed for the two enzymes by immunoblot analysis using polyclonal anti-tumor poly(A) polymerase antibodies or autoimmune sera which contain antibodies specific for the liver type enzyme. Results indicate that both tumor and liver type enzymes are conserved across species ranging from rat to human. The yeast enzyme does not appear to be immunologically related to the liver or the tumor type poly(A) polymerase. The liver type enzyme appears to be specific for normal tissues whereas the tumor type enzyme is detected only in tissues in a "tumorigenic" state or cell lines originating from tumor tissues.